(54.237.183.249)
Users online: 1660    [ij] [ij] [ij] 
Email id
 

Asian Journal of Pharmaceutical Research
Year : 2020, Volume : 10, Issue : 3
First page : ( 226) Last page : ( 232)
Print ISSN : 2231-5683. Online ISSN : 2231-5691.
Article DOI : 10.5958/2231-5691.2020.00039.8

Development of immunotherapeutic nanoparticles for treatment of tuberculosis

Patil Monesh O., Mali Yogesh S., Patil Paresh A.*, Karnavat D. R.

Ahinsa Institute of Pharmacy, Dondaicha, Tal-Shindkheda, Dhule, Maharashtra, 425408, India

*Corresponding Author E-mail: rcp.pareshpatil@gmail.com

Online published on 16 September, 2020.

Abstract

Tuberculosis (TB) is a leading infectious disease which causes for morbidity as well as mortality. This communicable infectious disease is caused by Mycobacterium tuberculosis. Nanoparticle-based drug delivery systems have considerable potential for treatment of tuberculosis (TB). The important technological advantages of nanoparticles used as drug carriers are high stability, high carrier capacity, feasibility of incorporation of both hydrophilic and hydrophobic substances, and feasibility of variable routes of administration, including oral application and inhalation.The main aim to develop these novel drug-delivery systems is to improve the patient compliance and reduce therapy time. It also reduces the dosage frequency and resolves the difficulty of low poor compliance. Nanoparticle based treatment shows convincing and promising outcomes in the treatment of tuberculosis. This article discuss various nanotechnology-based therapies which can be used for the treatment of TB.

Top

Keywords

Tuberculosis, Nanotechnology, Drug delivery system, Feasibility.

Top

  
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
446,694,481 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.